ArticleBasic & clinical pharmacology & toxicology2026
Proton Pump Inhibitors and Biomarkers of Haemostasis in Postmenopausal Women: The Buffalo OsteoPerio Study.
Article in Basic & clinical pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsExamine the association between proton pump inhibitor (PPI) use and plasma levels of four biomarkers of haemostasis: fibrinogen, von Willebrand factor (vWF), high-sensitivity CRP (hs-CRP) and plasminogen activator inhibitor-1 (PAI-1) in postmenopausal women.
methodsWe conducted a cross-sectional analysis on 200 women in the Buffalo Osteoporosis and Periodontitis study Year 17 visit. PPI use was assessed using medication inventories, and biomarkers were measured using frozen plasma samples. Linear regression was used to estimate mean differences for each biomarker according to PPI use (yes/no) and duration (≤ 1 year, > 1 year). Logistic regression was used to estimate the odds ratio (OR) and 95% confidence interval (95% CI) for having a high versus low level of each biomarker. Models were adjusted for major cardiovascular risk factors to account for potential confounding.
resultsPPI users had non-statistically significant higher levels of vWF (mean difference = 52.9 mIU/mL, p = 0.38) and log hs-CRP (mean difference = 0.1 mg/L, p = 0.5) compared to non-users. PPI users for > 1 year had non-statistically significant higher odds of having a high level of vWF (OR = 1.08, 95% CI: 0.51-2.31) and hs-CRP (OR = 1.16, 95% CI: 0.58-2.33) compared to non-users.
conclusionsThere was no significant association between PPI use and measured plasma haemostatic markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.